Category

News
Health of Bone Marrow Depots

The Dynamics of Healthy Bone Marrow Depots

One theme of the last few posts on Dr. Philippe Hernigou’s pioneering use of BMC to treat soft and bony tissue pathologies has been the need to boost the bone marrow cellularity and/or its vitality. What? You haven’t caught on that the real objective of treating orthopedic pathologies is to make sure the adjacent bone...
Read More
Avascular Necrosis

Hernigou Pioneered BMC Treatment of Avascular Necrosis of the Femoral Head

In the last post,I reviewed the therapeutic benefit reported by Dr. Philippe Hernigou for using BMC to treat ankle non-unions in diabetic patients. I will move on in this post to cover Dr. Hernigou’s use of BMC in another bony pathology, namely avascular necrosis of the femoral head, also referred to as osteonecrosis of the...
Read More
Non-unions in Diabetic Patients

Hernigou Closes the Gap on Diabetic Foot/Ankle Non-unions

In the last post, I reviewed the potent anti-microbial benefits of bone marrow concentrate (BMC) published in a paper by Dr. Philippe Hernigou in treating antibiotic-refectory infections in non-unions. I will move on in this post to cover Dr. Hernigou’s use of BMC in treating non-unions of the foot and ankle in diabetic patients. I...
Read More
Anti-microbial activity BMC orthopedic infections

A Recent Hernigou Paper on the Use of BMC as an Anti-microbial Agent

Continuing in my effort to review Dr. Philippe Hernigou’s publications on the use of bone marrow concentrate (BMC) in treating a variety of orthopedic pathologies, I would like to cover a very recent publication in which he presents clinical data supporting the use of BMC as a means of eliminating microbial infections in fracture sites....
Read More
Fractured Long Bone Non-Unions

Hernigou’s BMC Treatment of Fractured Long-bone Non-unions

In the last post, I focused solely on adverse events associated with the bone marrow aspiration (BMA) procedure itself. In this post, I would like to return to another of Dr. Hernigou’s classic publications on the use of BMC to treat long-bone non-unions. I covered his publication on the benefits of BMC-augmentation of a surgical...
Read More
Bone Marrow Aspiration

Bone Marrow Aspiration: The Real Deal on Adverse Events

As I reviewed the first clinical paper in my series highlighting the advantages of using bone marrow concentrate (BMC) in treating orthopedic pathologies (Part One and Part Two), I tried to fulfill my promise to the FDA to point out adverse events reported in the publication. However, I realized that by and large the adverse...
Read More
Intact Tendon

Fixing Rotator Cuff Tears with Bone Marrow Concentrate—Beating the Odds for an Intact Tendon at 10-Years – Part Two

In the previous post, I started reviewing a classic paper published by Dr. Philippe Hernigou and co-workers, entitled “Biological augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.” I will continue in this post by reporting on clinical outcomes from the study. Most importantly,...
Read More
Rotator Cuff

Fixing Rotator Cuff Tears with Bone Marrow Concentrate—Beating the Odds for an Intact Tendon at 10-Years – Part One

Dr. Philippe Hernigou published a paper in 2014 entitled “Biological augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.” I selected this paper to start my review of Dr. Hernigou’s extensive clinical study series on BMC therapy for orthopedic pathologies in part because it has...
Read More
Hernigou Treatment

Filling the FDA’s Gaps on BMC and Clinical Studies with the help of Dr. Hernigou

The past couple of posts (No Increased Cancer Risk from Your Autologous BMC Treatment and Making Sense of Your Environment—if You are a Stem Cell) have covered aspects of the puzzling and misleading article FDA personnel published in the New England Journal of Medicine (NEJM) last November. In particular, the authors complained about the lack...
Read More
Stem Cell

Making Sense of Your Environment—if You are a Stem Cell

In a previous post, I commented on a paper recently published in the New England Journal of Medicine (NEJM) in which FDA personnel expressed their dissatisfaction with the lack of solid, Level 1 clinical trials for the use of stem cell therapies by citing the lack of systematic recording of adverse events and a lack...
Read More
1 7 8 9 10